3 results
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
Primary Objective:To evaluate the effect of sonlicromanol on motor symptom severity in children with genetically confirmed mitochondrial disease affecting oxidative phosphorylation during a 6 month treatment period (GMFM).
The primary objective of the research is to find out if treatment with BMS-931699 can improve systemic lupus erythematosus (SLE) disease activity. This will be measured by determining the proportion of BICLA responders who achieve BILAG disease…